Torrent Pharmaceuticals quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	4,979	3,302	+50.8%
EBITDA	1,666	1,083	+53.8%
EBITDA margin	33.5%	32.8%	+0.7 pts
Profit before tax	737	791	−6.8%
Net profit	534	591	−9.6%
EPS	₹14.05	₹17.45	−19.5%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	4,979	4,921	4,197	3,303	3,302	3,178	2,959	2,809	2,889	2,859	2,745	2,732	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	−10.0	−12.0	−17.0	−13.0	−27.0	−37.0	−18.0	33.0	−16.0	24.0	31.0	−33.0
	4,969	4,909	4,180	3,290	3,275	3,141	2,941	2,842	2,873	2,883	2,776	2,699
	588	609	566	414	382	396	402	370	337	411	410	379
	593	531	477	422	382	338	416	420	382	313	315	327
	43.0	23.0	−28.0	−37.0	36.0	40.0	−87.0	−117	−41.0	−30.0	−46.0	−9.0
	895	893	788	651	627	605	561	549	543	550	486	496
	300	305	236	45.0	48.0	56.0	56.0	57.0	64.0	75.0	80.0	80.0
	609	593	508	206	204	201	201	199	198	197	203	213
	1,194	1,201	1,038	765	792	767	703	673	729	711	697	670
	4,222	4,155	3,585	2,466	2,471	2,403	2,252	2,151	2,212	2,227	2,145	2,156
	1,666	1,664	1,356	1,088	1,083	1,032	964	914	939	904	883	869
	1,057	1,071	848	882	879	831	763	715	741	707	680	656
Profit
	747	754	595	824	804	738	689	691	661	656	631	543
	−10.0	−21.0	−66.0	−10.0	−13.0	0.0	−24.0	0.0	0.0	0.0	0.0	88.0
	737	733	529	814	791	738	665	691	661	656	631	631
	298	254	166	244	233	201	184	153	156	126	142	106
	−95.0	−87.0	−1.0	−65.0	−33.0	−11.0	−17.0	35.0	52.0	73.0	40.0	82.0
	203	167	165	179	200	190	167	188	208	199	182	188
	534	566	364	635	591	548	498	503	453	457	449	443
	534	566	364	635	591	548	498	503	453	457	449	443
	−10.0	79.0	−86.0	−16.0	−76.0	−2.0	36.0	−70.0	−25.0	−34.0	1.0	−1.0
	524	645	278	619	515	546	534	433	428	423	450	442
	534	566	389	635	591	548	498	—	—	457	449	442
	0.0	0.0	−25.0	0.0	0.0	0.0	0.0	—	—	0.0	0.0	0.0
Per share
	₹14.05	₹14.87	₹11.51	₹18.77	₹17.45	₹16.19	₹14.71	₹14.88	₹13.37	₹13.51	₹13.27	₹13.10
	₹14.05	₹14.87	₹11.51	₹18.77	₹17.45	₹16.19	₹14.71	₹14.88	₹13.37	₹13.51	₹13.27	₹13.10
Other comprehensive income — detail
	−10.0	79.0	−86.0	−16.0	−76.0	−2.0	36.0	—	—	—	—	—
	−12.0	−17.0	21.0	−9.0	−3.0	−9.0	−9.0	−7.0	−7.0	−5.0	4.0	−6.0
	−3.0	−4.0	4.0	−1.0	−1.0	−2.0	1.0	—	—	—	—	—
	—	—	—	—	—	—	—	−3.0	−2.0	−2.0	2.0	−2.0
	3.0	119	−127	−7.0	−92.0	−2.0	52.0	−68.0	−33.0	−29.0	4.0	−2.0
	4.0	27.0	−24.0	1.0	−18.0	−7.0	6.0	—	—	—	—	—
	—	—	—	—	—	—	—	−2.0	−13.0	2.0	5.0	−5.0
	524	645	302	619	515	546	534	433	428	423	450	442
	0.0	0.0	−24.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹14.05	₹14.87	₹11.51	₹18.77	₹17.45	₹16.19	₹14.71	₹14.88	₹13.37	₹13.51	₹13.27	₹13.10
	₹14.05	₹14.87	₹11.51	₹18.77	₹17.45	₹16.19	₹14.71	₹14.88	₹13.37	₹13.51	₹13.27	₹13.10
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,755	3,758	3,182	2,504	2,502	2,404	2,228	2,136	2,211	2,165	2,066	2,035
	75.4%	76.4%	75.8%	75.8%	75.8%	75.6%	75.3%	76.0%	76.5%	75.7%	75.3%	74.5%
Adjusted (ex-exceptional items) — derived
	747	754	595	824	804	738	689	691	661	656	631	543
	−10.0	−21.0	−66.0	−10.0	−13.0	0.0	−24.0	0.0	0.0	0.0	0.0	88.0
	541	582	409	643	601	548	516	503	453	457	449	381
	₹14.24	₹15.30	₹12.95	₹19.00	₹17.74	₹16.19	₹15.24	₹14.88	₹13.37	₹13.51	₹13.27	₹11.27

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TORNTPHARM₹4,557.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA JBCHEPHARM MANKIND ZYDUSLIFE DIVISLAB MAXHEALTH DRREDDY CIPLAMcap ₹1.54L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	2,732.0	2,745.0	2,859.0	2,889.0	2,809.0	2,959.0	3,178.0	3,302.0	3,303.0	4,197.0	4,921.0	4,979.0
Other Income	-33.0	31.0	24.0	-16.0	33.0	-18.0	-37.0	-27.0	-13.0	-17.0	-12.0	-10.0
Total Income	2,699.0	2,776.0	2,883.0	2,873.0	2,842.0	2,941.0	3,141.0	3,275.0	3,290.0	4,180.0	4,909.0	4,969.0
Expenses
+ Cost of Materials Consumed	379.0	410.0	411.0	337.0	370.0	402.0	396.0	382.0	414.0	566.0	609.0	588.0
+ Purchases of Stock-in-Trade	327.0	315.0	313.0	382.0	420.0	416.0	338.0	382.0	422.0	477.0	531.0	593.0
+ Changes in Inventories	-9.0	-46.0	-30.0	-41.0	-117.0	-87.0	40.0	36.0	-37.0	-28.0	23.0	43.0
+ Employee Benefit Expense	496.0	486.0	550.0	543.0	549.0	561.0	605.0	627.0	651.0	788.0	893.0	895.0
+ Finance Costs	80.0	80.0	75.0	64.0	57.0	56.0	56.0	48.0	45.0	236.0	305.0	300.0
+ Depreciation & Amortisation	213.0	203.0	197.0	198.0	199.0	201.0	201.0	204.0	206.0	508.0	593.0	609.0
+ Other Expenses	670.0	697.0	711.0	729.0	673.0	703.0	767.0	792.0	765.0	1,038.0	1,201.0	1,194.0
Total Expenses	2,156.0	2,145.0	2,227.0	2,212.0	2,151.0	2,252.0	2,403.0	2,471.0	2,466.0	3,585.0	4,155.0	4,222.0
EBITDA	869.0	883.0	904.0	939.0	914.0	964.0	1,032.0	1,083.0	1,088.0	1,356.0	1,664.0	1,666.0
EBIT	656.0	680.0	707.0	741.0	715.0	763.0	831.0	879.0	882.0	848.0	1,071.0	1,057.0
Profit
PBT before Exceptional Items	543.0	631.0	656.0	661.0	691.0	689.0	738.0	804.0	824.0	595.0	754.0	747.0
+ Exceptional Items	88.0	0.0	0.0	0.0	0.0	-24.0	0.0	-13.0	-10.0	-66.0	-21.0	-10.0
Pretax Income	631.0	631.0	656.0	661.0	691.0	665.0	738.0	791.0	814.0	529.0	733.0	737.0
+ Current Tax	106.0	142.0	126.0	156.0	153.0	184.0	201.0	233.0	244.0	166.0	254.0	298.0
+ Deferred Tax	82.0	40.0	73.0	52.0	35.0	-17.0	-11.0	-33.0	-65.0	-1.0	-87.0	-95.0
Tax Expense	188.0	182.0	199.0	208.0	188.0	167.0	190.0	200.0	179.0	165.0	167.0	203.0
Net Income	443.0	449.0	457.0	453.0	503.0	498.0	548.0	591.0	635.0	364.0	566.0	534.0
+ Net Income — Continuing Ops	443.0	449.0	457.0	453.0	503.0	498.0	548.0	591.0	635.0	364.0	566.0	534.0
+ Other Comprehensive Income	-1.0	1.0	-34.0	-25.0	-70.0	36.0	-2.0	-76.0	-16.0	-86.0	79.0	-10.0
Total Comprehensive Income	442.0	450.0	423.0	428.0	433.0	534.0	546.0	515.0	619.0	278.0	645.0	524.0
Net Income to Common	442.0	449.0	457.0	—	—	498.0	548.0	591.0	635.0	389.0	566.0	534.0
Minority Interest	0.0	0.0	0.0	—	—	0.0	0.0	0.0	0.0	-25.0	0.0	0.0
Per Share
Basic EPS	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87	14.05
Diluted EPS	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87	14.05
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	36.0	-2.0	-76.0	-16.0	-86.0	79.0	-10.0
+ Items NOT to be Reclassified to P&L	-6.0	4.0	-5.0	-7.0	-7.0	-9.0	-9.0	-3.0	-9.0	21.0	-17.0	-12.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	1.0	-2.0	-1.0	-1.0	4.0	-4.0	-3.0
+ Tax on Items NOT to be Reclassified — alt tag	-2.0	2.0	-2.0	-2.0	-3.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-2.0	4.0	-29.0	-33.0	-68.0	52.0	-2.0	-92.0	-7.0	-127.0	119.0	3.0
+ Tax on Items to be Reclassified	—	—	—	—	—	6.0	-7.0	-18.0	1.0	-24.0	27.0	4.0
+ Tax on Items to be Reclassified — alt tag	-5.0	5.0	2.0	-13.0	-2.0	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	442.0	450.0	423.0	428.0	433.0	534.0	546.0	515.0	619.0	302.0	645.0	524.0
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-24.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87	14.05
Diluted EPS — Continuing Operations	13.10	13.27	13.51	13.37	14.88	14.71	16.19	17.45	18.77	11.51	14.87	14.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,035.0	2,066.0	2,165.0	2,211.0	2,136.0	2,228.0	2,404.0	2,502.0	2,504.0	3,182.0	3,758.0	3,755.0
Gross Margin %	74.49	75.26	75.73	76.53	76.04	75.30	75.65	75.77	75.81	75.82	76.37	75.42
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	543.0	631.0	656.0	661.0	691.0	689.0	738.0	804.0	824.0	595.0	754.0	747.0
− Exceptional Items (reconciliation)	88.0	0.0	0.0	0.0	0.0	-24.0	0.0	-13.0	-10.0	-66.0	-21.0	-10.0
Net Income Adj (tax-effected)	381.2	449.0	457.0	453.0	503.0	516.0	548.0	600.7	642.8	409.4	582.2	541.2
EPS Adj	11.27	13.27	13.51	13.37	14.88	15.24	16.19	17.74	19.00	12.95	15.30	14.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Filed Debt Equity	—	—	—	—	—	0.40	—	—	—	—	—	—
Filed Dscr	—	—	—	—	—	4.91	—	—	—	—	—	—
Filed Iscr	—	—	—	—	—	13.66	—	—	—	—	—	—
Paid Up Equity Capital	169.2	169.2	169.2	169.2	169.2	169.2	169.2	169.2	169.2	169.2	169.2	190.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Torrent Pharma Q2 FY27 results (July–September 2026)

Filed with NSE on Friday, 23 October 2026 at 4:45 pm IST

Torrent Pharmaceuticals (NSE: TORNTPHARM) reported its Q2 FY27 results (July–September 2026) on Friday, 23 October 2026 at 4:45 pm IST. Consolidated net profit was ₹534 crore, down 9.6% from ₹591 crore in Q2 FY26 and down 5.7% from ₹566 crore in Q1 FY27. Revenue from operations was ₹4,979 crore, up 50.8% year on year and up 1.2% from the previous quarter.

Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹534 Cr−9.6% vs Q2 FY26−5.7% vs Q1 FY27
Revenue from operations: ₹4,979 Cr+50.8% vs Q2 FY26+1.2% vs Q1 FY27
Operating margin (EBIT): 21.2%−5.4 pts vs Q2 FY26−0.5 pts vs Q1 FY27EBIT ₹1,057 Cr
EBITDA: ₹1,666 Cr+53.8% vs Q2 FY26+0.1% vs Q1 FY27margin 33.5%
Earnings per share (basic): ₹14.05−19.5% vs Q2 FY26−5.5% vs Q1 FY27
Net profit margin: 10.7%−7.2 pts vs Q2 FY26−0.8 pts vs Q1 FY27

Questions

What was Torrent Pharma's net profit in Q2 FY27?

Consolidated net profit was ₹534 crore, down 9.6% from ₹591 crore in Q2 FY26 and down 5.7% from ₹566 crore in Q1 FY27.

What is Torrent Pharma's net profit margin?

Torrent Pharma's net profit margin was 10.7% in Q2 FY27 (net profit as a share of revenue from operations), against 17.9% in Q2 FY26 (down 7.2 percentage points). For FY26 as a whole it was 15.5%.

What was Torrent Pharma's net profit in FY26?

Consolidated net profit was ₹2,163 crore in FY26 (April 2025–March 2026), up 13.2% from ₹1,911 crore in FY25. It was ₹1,656 crore in FY24 and ₹1,245 crore in FY23: up 73.7% over three years, 20.2% a year on average.

What was Torrent Pharma's revenue in Q2 FY27?

Revenue from operations was ₹4,979 crore, up 50.8% year on year and up 1.2% from the previous quarter.

What was Torrent Pharma's EPS in Q2 FY27?

Basic earnings per share were ₹14.05, against ₹17.45 in Q2 FY26.

When did Torrent Pharma announce its Q2 FY27 results?

On Friday, 23 October 2026 at 4:45 pm IST, in its results filing to the stock exchanges.

How were Torrent Pharma's Q2 FY27 results?

Revenue grew from a year earlier while net profit fell: revenue was up 50.8% at ₹4,979 crore, and net profit was down 9.6% at ₹534 crore. The operating margin was 21.2%, down 5.4 percentage points from 26.6% a year earlier. Against Q1 FY27, net profit was down 5.7% and revenue up 1.2%.

What was Torrent Pharma's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹1,057 crore, a margin of 21.2%, against 21.8% in Q1 FY27 and 26.6% in Q2 FY26. EBITDA was ₹1,666 crore, 33.5% of revenue.

What was Torrent Pharma's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹1,100 crore, down 3.4% from ₹1,139 crore in the same months a year earlier. Revenue from operations was ₹9,900 crore, up 52.8%.

How has Torrent Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹635 crore in Q3 FY26, ₹389 crore in Q4 FY26, ₹566 crore in Q1 FY27 and ₹534 crore in Q2 FY27. That is ₹2,124 crore over the four quarters, down 0.7% from ₹2,140 crore in the four quarters before. Revenue from operations: ₹3,303 crore, ₹4,197 crore, ₹4,921 crore and ₹4,979 crore.

What was Torrent Pharma's revenue in FY26?

Revenue from operations was ₹13,980 crore in FY26 (April 2025–March 2026), up 21.4% from ₹11,516 crore in FY25. It was ₹10,728 crore in FY24 and ₹9,620 crore in FY23: up 45.3% over three years, 13.3% a year on average.

When will Torrent Pharma announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Torrent Pharma figures come from?

From Torrent Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 23 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.